Roswell Park's Dr. Eunice Wang will present pivotal results from the KOMET-001 trial showing clinical activity of menin inhibitor ziftomenib in patients with relapsed/refractory NPM1-mutant acute myeloid leukemia at ASCO 2025.
Kura Oncology has dosed first patients in KOMET-015, a Phase 1 trial evaluating ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
Preclinical data for Kura Oncology's next-generation farnesyl transferase inhibitor KO-2806 in combination with cabozantinib has been selected for oral presentation at the 2025 AACR Annual Meeting.
Ziftomenib, a selective oral menin inhibitor developed by Kura Oncology and Kyowa Kirin, has successfully met primary endpoints in the Phase II Komet-001 registrational trial for acute myeloid leukemia.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.